Christoph Hatz
Ready-To-Go Questionnaire - Development and validation of a novel medical pre-travel risk stratification tool
Gazzotti A, De Crom-Beer S, Haller S, Hasler T, Anagnostopoulos A, Hatz C, Fehr J. Ready-To-Go Questionnaire - Development and validation of a novel medical pre-travel risk stratification tool. Travel Medicine and Infectious Disease 2022; 47
May 5, 2022Ready-To-Go Questionnaire - Development and validation of a novel medical pre-travel risk stratification tool
May 5, 2022Travel Medicine and Infectious Disease 2022; 47
Gazzotti Anna, De Crom-Beer Susan, Haller Sabine, Hasler Thomas, Anagnostopoulos Alexia, Hatz Christoph, Fehr Jan
Leptospirosis Followed by Kawasaki-Like Disease: Case Report From an Adult Swiss Patient and Review of the Literature.
Baerlocher S, Helfenstein S, Mahr A, Crippa S, Garcia Boy R, Kahlert C, Yurttas T, Hatz C, Kohler P. Leptospirosis Followed by Kawasaki-Like Disease: Case Report From an Adult Swiss Patient and Review of the Literature. Open Forum Infect Dis 2021; 8:ofab088.
Feb 24, 2021Leptospirosis Followed by Kawasaki-Like Disease: Case Report From an Adult Swiss Patient and Review of the Literature.
Feb 24, 2021Open Forum Infect Dis 2021; 8:ofab088
Baerlocher Severin, Helfenstein Seth, Mahr Alfred, Crippa Selina, Garcia Boy Regine, Kahlert Christian, Yurttas Timur, Hatz Christoph, Kohler Philipp
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Huttner A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Kuhn A, de Vallière S, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer A, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, Fonck V. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017; 17:528-537.
Feb 24, 2017Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Feb 24, 2017Lancet Infect Dis 2017; 17:528-537
Huttner Angela, Bernasconi Enos, Viereck Volker, Kavvadias Tilemachos, Kling Kerstin, Ryu Gloria, Hülder Tanja, Gröger Sabine, Scheiner David, Alaimo Cristina, Harbarth Stephan, Poolman Jan, Kuhn Anette, de Vallière Serge, Hatz Christoph, van den Dobbelsteen Germie, Abbanat Darren, Hornacek Alena, Frölich Rahel, Dreyer Anita M, Martin Patricia, Davies Todd, Fae Kellen, van den Nieuwenhof Ingrid, Thoelen Stefan, Fonck Veronica Gambillara
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients
Veit O, Furrer H, Hatz C, Staub T, Litzba N, Bae H, Schmid P, Mossdorf E, Cavassini M, Chapuis-Taillard C, Niedrig M, Swiss HIV Cohort Study. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48:659-66.
Mar 1, 2009Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients
Mar 1, 2009Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48:659-66
Veit Olivia, Furrer Hansjakob, Hatz Christoph, Staub Thomas, Litzba Nadine, Bae Hi-Gung, Schmid Patrick, Mossdorf Erik, Cavassini Matthias, Chapuis-Taillard Caroline, Niedrig Matthias, Swiss HIV Cohort Study